Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 17, 2017
Trial Information
Current as of August 19, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Brain amyloid will be measured using PET with \[11C\]PiB. Participation will involve an initial brain scan and possibly a follow-up brain scan two years later.
The data collected in this study will help explain amyloid deposits in several groups of participants including adults with and without signs of memory impairment. The information collected will help find out who is more likely to have brain amyloid and when it increases the risk for developing memory problems. Research studies suggest that people with elevated levels of brain amyloid are at an increased risk for memory decline, but...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Enrolled in a study with the Alzheimer's Disease Research Center.
- Exclusion Criteria:
- • -
About Wake Forest University Health Sciences
Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Winston Salem, North Carolina, United States
Patients applied
Trial Officials
Suzanne Craft, PhD
Principal Investigator
Wake Forest University Health Sciences
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials